#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17984	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2316	768.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1452	1452	C	1043	C	975	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33588	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3465	959.9	0	.	n	.	0	T695C	SNP	695	695	T	989	989	C	1097	C,A	1003,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33588	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3465	959.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1631	1631	A	1131	A,G	1045,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33588	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3465	959.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2265	2265	C	1042	C	959	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33588	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3465	959.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2891	2891	T	985	T,C	919,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	33588	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3465	959.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2339	2339	A	1033	A	966	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2382	folP	852	852	100.0	folP.l15.c4.ctg.1	1471	159.8	1	SNP	p	R228S	1	.	.	682	684	AGC	973	975	AGC	231;228;232	A;G;C	214;209;213	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6204	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3430	179.3	1	SNP	p	S91F	0	.	.	271	273	TCC	602	604	TCC	191;190;191	T;C;C	180;177;179	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6204	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3430	179.3	1	SNP	p	D95G	0	.	.	283	285	GAC	614	616	GAC	187;187;190	G;A;C	171;170;174	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6204	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3430	179.3	1	SNP	p	D95N	0	.	.	283	285	GAC	614	616	GAC	187;187;190	G;A;C	171;170;174	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1790	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1288	138.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	445	447	ACC	203;202;202	A,G;C;C	180,1;186;189	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1790	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1288	138.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	460	462	CAC	201;203;203	C,A;A,G;C	182,1;180,1;183	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1790	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1288	138.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	643	645	CAC	229;229;228	C,T;A;C	209,1;207;207	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1790	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1288	138.1	1	SNP	p	G45D	0	.	.	133	135	GGC	463	465	GGC	202;204;204	G;G;C	183;184;178	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	996	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	993	99.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5834	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2900	199.1	1	SNP	p	D86N	0	.	.	256	258	GAC	550	552	GAC	231;231;238	G;A;C	222;219;228	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5834	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2900	199.1	1	SNP	p	S87I	0	.	.	259	261	AGT	553	555	AGT	238;239;237	A,C;G;T	227,1;228;226	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5834	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2900	199.1	1	SNP	p	S87R	0	.	.	259	261	AGT	553	555	AGT	238;239;237	A,C;G;T	227,1;228;226	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5834	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2900	199.1	1	SNP	p	S87W	0	.	.	259	261	AGT	553	555	AGT	238;239;237	A,C;G;T	227,1;228;226	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5834	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2900	199.1	1	SNP	p	S88P	0	.	.	262	264	TCC	556	558	TCC	238;241;236	T;C;C	227;228;226	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4884	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2557	189.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1510	1512	GGC	227;224;224	G;G;C	208;203;200	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1291	1293	GCA	230;229;231	G;C;A	209;204;210	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1294	1296	ATC	235;234;233	A;T;C	213;211;212	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1306	1308	GTG	231;226;227	G;T;G	212;205;208	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1306	1308	GTG	231;226;227	G;T;G	212;205;208	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1810	1812	ACC	239;237;235	A;C,A;C	212;211,1;210	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1864	1866	GCG	221;221;219	G;C,G;G	184;163,1;173	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1864	1866	GCG	221;221;219	G;C,G;G	184;163,1;173	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1987	1989	GGC	182;180;179	G;G;C	172;172;170	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1996	1998	GGC	178;177;179	G;G;C	166;167;166	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4538	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2491	180.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2014	2016	CCG	157;162;159	C,CG,CGG;CG,CGGGG;G	114,1,1;120,1;117	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6282	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3069	202.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2428	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1683	142.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	520	520	C	160	C	146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	456	458	GGA	235;236;238	G;G;A	212;211;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	G50D	NONSYN	148	150	GGC	462	464	GAC	243;244;247	G;A,G;C	217;218,1;223	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	F135L	NONSYN	403	405	TTT	717	719	CTT	239;241;240	C;T;T	222;221;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	R143G	NONSYN	427	429	AGA	741	743	GGA	245;245;245	G;G;A,T	229;229;222,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	D171G	NONSYN	511	513	GAT	825	827	GGT	233;235;236	G;G;T	223;225;215	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	G189S	NONSYN	565	567	GGC	879	881	AGC	264;263;260	A;G;C,A	236;235;236,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	945	945	T	249	T	230	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	1	SNP	p	G120K	0	.	.	358	360	GGT	672	674	GGT	271;267;267	G;G;T	246;243;238	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	1	SNP	p	A121D	0	.	.	361	363	GCC	675	677	GCC	263;266;267	G;C;C	239;246;247	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	1	SNP	p	A121N	0	.	.	361	363	GCC	675	677	GCC	263;266;267	G;C;C	239;246;247	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	HET	.	.	.	G137A	.	137	137	G	451	451	G	241	G,A	140,75	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	667	3162	porB1b	1035	1035	96.28	porB1b.l15.c4.ctg.1	1544	202.6	0	HET	.	.	.	A394G	.	394	394	A	708	708	A	241	A,G	189,29	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	12362	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4803	255.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1946	1948	AAT	290;288;288	A;A;T,A	262;258;254,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1308	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1006	129.0	1	SNP	p	V57M	1	.	.	169	171	ATG	485	487	ATG	269;270;263	A;T;G	257;256;251	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
